Abbott Laboratories Cash Flow Conversion Efficiency
Abbott Laboratories cash flow conversion efficiency. Based on the latest financial reports, Abbott Laboratories (ABT) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.79 Billion) by net assets ($51.26 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Abbott Laboratories (1989–2024)
Cash flow conversion efficiency of Abbott Laboratories from 1989 to 2024. This chart illustrates how Abbott Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Abbott Laboratories stock price today for real-time trading data and today's change.
Abbott Laboratories Cash Flow Conversion Ratio Explained
Abbott Laboratories cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Abbott Laboratories Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abbott Laboratories ranked by their cash flow conversion efficiency. Also see ABT market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shopify Inc
TO:SHOP
|
0.052x |
|
Mitsubishi UFJ Financial Group Inc ADR
NYSE:MUFG
|
0.351x |
|
Commonwealth Bank of Australia
AU:CBA
|
-0.024x |
|
Verizon Communications Inc
SA:VERZ34
|
0.099x |
|
SHELL PLC WI ADR/2
F:L3H
|
0.118x |
|
Reliance Industries Limited
NSE:RELIANCE
|
0.091x |
|
McDonald’s Corporation
NYSE:MCD
|
-1.876x |
|
Verizon Communications Inc
NYSE:VZ
|
0.099x |
Annual Cash Flow Conversion Efficiency for Abbott Laboratories (1989–2024)
The table below shows the annual cash flow conversion efficiency of Abbott Laboratories from 1989 to 2024. Review Abbott Laboratories (ABT) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $47.90 Billion | $8.56 Billion | 0.179x | -4.46% |
| 2023-12-31 | $38.83 Billion | $7.26 Billion | 0.187x | -27.97% |
| 2022-12-31 | $36.91 Billion | $9.58 Billion | 0.260x | -11.21% |
| 2021-12-31 | $36.02 Billion | $10.53 Billion | 0.292x | +22.13% |
| 2020-12-31 | $33.00 Billion | $7.90 Billion | 0.239x | +22.12% |
| 2019-12-31 | $31.30 Billion | $6.14 Billion | 0.196x | -4.40% |
| 2018-12-31 | $30.72 Billion | $6.30 Billion | 0.205x | +14.49% |
| 2017-12-31 | $31.10 Billion | $5.57 Billion | 0.179x | +28.96% |
| 2016-12-31 | $23.06 Billion | $3.20 Billion | 0.139x | +12.76% |
| 2015-12-31 | $24.08 Billion | $2.97 Billion | 0.123x | -19.04% |
| 2014-12-31 | $24.16 Billion | $3.67 Billion | 0.152x | +15.65% |
| 2013-12-31 | $25.27 Billion | $3.32 Billion | 0.132x | -62.13% |
| 2012-12-31 | $26.81 Billion | $9.31 Billion | 0.347x | -5.02% |
| 2011-12-31 | $24.53 Billion | $8.97 Billion | 0.366x | -1.25% |
| 2010-12-31 | $23.59 Billion | $8.74 Billion | 0.370x | +17.41% |
| 2009-12-31 | $23.06 Billion | $7.28 Billion | 0.315x | -24.92% |
| 2008-12-31 | $17.48 Billion | $7.34 Billion | 0.420x | +44.10% |
| 2007-12-31 | $17.78 Billion | $5.18 Billion | 0.292x | -23.11% |
| 2006-12-31 | $14.05 Billion | $5.33 Billion | 0.379x | +5.64% |
| 2005-12-31 | $14.42 Billion | $5.17 Billion | 0.359x | +16.66% |
| 2004-12-31 | $14.33 Billion | $4.41 Billion | 0.308x | +7.36% |
| 2003-12-31 | $13.07 Billion | $3.75 Billion | 0.287x | -26.93% |
| 2002-12-31 | $10.66 Billion | $4.18 Billion | 0.392x | -0.38% |
| 2001-12-31 | $9.06 Billion | $3.57 Billion | 0.394x | +8.87% |
| 2000-12-31 | $8.57 Billion | $3.10 Billion | 0.362x | -8.56% |
| 1999-12-31 | $7.43 Billion | $2.94 Billion | 0.395x | -17.32% |
| 1998-12-31 | $5.71 Billion | $2.73 Billion | 0.478x | -9.05% |
| 1997-12-31 | $5.00 Billion | $2.63 Billion | 0.526x | +6.42% |
| 1996-12-31 | $4.82 Billion | $2.38 Billion | 0.494x | +10.55% |
| 1995-12-31 | $4.40 Billion | $1.97 Billion | 0.447x | -18.17% |
| 1994-12-31 | $4.05 Billion | $2.21 Billion | 0.546x | +8.70% |
| 1993-12-31 | $3.67 Billion | $1.85 Billion | 0.503x | +21.14% |
| 1992-12-31 | $3.35 Billion | $1.39 Billion | 0.415x | -8.56% |
| 1991-12-31 | $3.20 Billion | $1.45 Billion | 0.454x | +7.05% |
| 1990-12-31 | $2.83 Billion | $1.20 Billion | 0.424x | +20.37% |
| 1989-12-31 | $2.73 Billion | $959.90 Million | 0.352x | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more